Ajanta Pharma Announces The Approval And Launch Of Omeprazole And Sodium Bicarbonate Capsules
BRIDGEWATER, N.J., July 18, 2016 /PRNewswire/ -- Ajanta Pharma USA Inc., a wholly owned subsidiary of Ajanta Pharma Ltd, announces today the launch of Omeprazole and Sodium Bicarbonate Capsules (20mg/1100mg and 40mg/1100mg), a bioequivalent prescription generic version of Zegerid®1 Capsules, into the US market.
Omeprazole and Sodium Bicarbonate Capsules is part of an ever-growing portfolio of products that Ajanta has developed for the U.S. market. In total, Ajanta has 26 Abbreviated New Drug Applications (ANDAs) of which it has 11 final ANDA approvals; 1 tentative approval; and 14 ANDAs under review with the United States Food & Drug Administration (FDA).
About Ajanta Pharma
Ajanta Pharma Ltd is a specialty pharmaceutical company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing quality, pharmaceuticals across 30 countries.
For more details about Ajanta Pharma USA Inc., please visit us at www.ajantapharmausa.com.
1 Zegerid® is a registered trademark of Santarus Inc.
Photo - http://photos.prnewswire.com/prnh/20160718/390588
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ajanta-pharma-announces-the-approval-and-launch-of-omeprazole-and-sodium-bicarbonate-capsules-300300061.html
SOURCE Ajanta Pharma USA Inc.
